Immunocore shows promise in treating melanoma

9th April 2014

Oxford-based Immunocore has announced that its immune therapy has shown promising early signs of efficacy in a Phase I trial in advanced melanoma patients.

Mark Middleton MD, Professor of Experimental Cancer Medicine at the University of Oxford, was Principal Investigator for the trial, the results of which were presented at the American Association for Cancer Research meeting in San Diego. Immunocore has its roots in Avidex, a company spun out by Oxford University Innovation in 1999 based on the work of Dr Bent Jakobsen.

For more information, please click here.

Press release sign up